we retrospectively analyzed R/R FLT3-ITD AML patients aged ≥ 18 years treated with intensive chemotherapy and sorafenib...Patients with NPM1 mutation had a CR/CRi rate of 88% vs. 50% in the remaining ones....For the 14 patients achieving CR/CRi, median relapse-free survival (RFS) was of 5 months, with 4-year RFS of 35.7%....sorafenib in association with high-dose CHT represented a feasible second line option for the treatment of FLT3-ITD positive R/R AML, with encouraging rates of CR/CRi, especially in NPM1-mutated cases...